Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREPARE-iVAC
2023-503894-39-00Phase 4Completed
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2023
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus, mycophenolate mofetil, mycophenolic acid, raxtozinameran and herpes zoster vaccine (recombinant, adjuvanted) in coronavirus disease 2019 (COVID-19) and herpes zoster (HZ) (2 arms), sponsored by University Medical Center Groningen. Started Aug 2023; status: completed.
02
Drugs
everolimusmycophenolate mofetilmycophenolic acidraxtozinameranherpes zoster vaccine (recombinant, adjuvanted)
03
Conditions
coronavirus disease 2019 (COVID-19)herpes zoster (HZ)
Beyond the preview
Go deeper on 2023-503894-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503894-39-00.